Fate Therapeutics
Skip to content
  • About Us
    • Overview
    • Leadership
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT819
      • FT825
      • FT836
      • FT839
      • FT522
    • Early/Expanded Access Policy
  • Science
    • Our Cells of Interest
    • iPSC Platform
    • Manufacturing
    • Publications & Presentations
  • Patients
    • Our Mission
    • Patient Education
    • Clinical Trials
  • Collaborations
  • Careers and Culture
    • The Fate Way
    • Join Our Team
  • Investors
    • About Fate
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
  • About Us
    • Overview
    • Leadership
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT819
      • FT825
      • FT836
      • FT839
      • FT522
    • Early/Expanded Access Policy
  • Science
    • Our Cells of Interest
    • iPSC Platform
    • Manufacturing
    • Publications & Presentations
  • Patients
    • Our Mission
    • Patient Education
    • Clinical Trials
  • Collaborations
  • Careers and Culture
    • The Fate Way
    • Join Our Team
  • Investors
    • About Fate
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact
2022 ASH Poster Presentation, Publications

Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection

©2025 Fate Therapeutics | 12278 Scripps Summit Drive, San Diego, CA 92131 | 866.875.1833 | LEGAL | PRIVACY

MENU
  • About Us
    • Overview
    • Leadership
    • Corporate Responsibility
  • Pipeline
    • Overview
    • Product Candidates
      • FT819
      • FT825
      • FT836
      • FT839
      • FT522
    • Early/Expanded Access Policy
  • Science
    • Our Cells of Interest
    • iPSC Platform
    • Manufacturing
    • Publications & Presentations
  • Patients
    • Our Mission
    • Patient Education
    • Clinical Trials
  • Collaborations
  • Careers and Culture
    • The Fate Way
    • Join Our Team
  • Investors
    • About Fate
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historical Stock Lookup
    • Investors FAQs
  • Contact

We are using cookies to give you the best experience on our website. To find out more about the information we collect please visit our Privacy Policy

You can find out more about which cookies we are using or switch them off in .

FATE Logo
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

For more information about the data we collect please visit our Privacy Policy.

Strictly Necessary Cookies

Strictly Necessary Cookies is enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!